HRP20171585T1 - Antitijela koja vezuju i blokiraju aktivirajući receptor eksprimiran na mijeloičnim stanicama 1 (trem-1) - Google Patents
Antitijela koja vezuju i blokiraju aktivirajući receptor eksprimiran na mijeloičnim stanicama 1 (trem-1) Download PDFInfo
- Publication number
- HRP20171585T1 HRP20171585T1 HRP20171585TT HRP20171585T HRP20171585T1 HR P20171585 T1 HRP20171585 T1 HR P20171585T1 HR P20171585T T HRP20171585T T HR P20171585TT HR P20171585 T HRP20171585 T HR P20171585T HR P20171585 T1 HRP20171585 T1 HR P20171585T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- seq
- acid residues
- sequence
- represented
- Prior art date
Links
- 108010066451 Triggering Receptor Expressed on Myeloid Cells-1 Proteins 0.000 title claims 4
- 102000018368 Triggering Receptor Expressed on Myeloid Cells-1 Human genes 0.000 title claims 4
- 150000001413 amino acids Chemical class 0.000 claims 20
- 125000000539 amino acid group Chemical group 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 6
- 230000027455 binding Effects 0.000 claims 5
- 101000795107 Homo sapiens Triggering receptor expressed on myeloid cells 1 Proteins 0.000 claims 3
- 102220481756 Thymocyte selection-associated high mobility group box protein TOX_Y28S_mutation Human genes 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 102200112366 rs587777527 Human genes 0.000 claims 2
- 102220044643 rs587781450 Human genes 0.000 claims 2
- 102200038304 rs61758405 Human genes 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 101000731015 Homo sapiens Peptidoglycan recognition protein 1 Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 102100032393 Peptidoglycan recognition protein 1 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Claims (10)
1. Antitijelo ili njegov fragment koje je sposobno za specifično vezivanje i blokiranje TREM-1, gdje je antitijelo ili njegov fragment sposoban za blokiranje PGLYRP1-inducirane aktivacije TREM-1, i ima epitop koji sadrži jedan, dva, tri, četiri, pet, šest, sedam ili sve od aminokiselinskih ostataka D38, V39, K40, C41, D42, Y43, T44 i L45 i jedan, dva ili sve od aminokiselinskih ostataka E46, K47, F48 sekvence sa identifikacijskim brojem - SEQ ID NO:1 koja predstavlja aminokiselinsku sekvencu humanog TREM-1.
2. Antitijelo ili njegov fragment u skladu sa patentnim zahtjevom 1, koje se natječe sa mAb 0170 za vezivanje za SEQ ID NO:1 koja predstavlja aminokiselinsku sekvencu humanog TREM-1, gdje mAb 0170 sadrži teški lanac koji sadrži sekvencu SEQ ID NO: 4, i laki lanac koji sadrži sekvencu SEQ ID NO: 5.
3. Antitijelo ili njegov fragment u skladu sa patentnim zahtjevom 1 ili 2, koji se natječe sa mAb 0170 za vezivanje za SEQ ID NO: 12 ili SEQ ID NO: 21 koja predstavlja aminokiselinske sekvence TREM-1 cinomolgus majmuna, gdje mAb 0170 sadrži teški lanac koji sadrži sekvencu SEQ ID NO: 4, i laki lanac koji sadrži sekvencu SEQ ID NO: 5.
4. Antitijelo ili njegov fragment u skladu sa bilo kojim od patentnih zahtjeva 1-3, koje je sposobno za specifično vezivanje polipeptida koji sadrži aminokiseline D38 do F48 sa SEQ ID NO: 1 koja predstavlja aminokiselinsku sekvencu humanog TREM-1.
5. Antitijelo u skladu sa bilo kojim od patentnih zahtjeva 1-4, koje je sposobno za specifično vezivanje SEQ ID NO: 13 koja predstavlja aminokiselinsku sekvencu K20A-hTREM-1-Cmyc2-His6.
6. Antitijelo u skladu sa bilo kojim od patentnih zahtjeva 1-5, koje je sposobno za specifično vezivanje SEQ ID NO: 14 koja predstavlja aminokiselinsku sekvencu A24T/Y28F/N30S/R32Q/P70H-cTREM-1-Cmyc2-His6.
7. Antitijelo u skladu sa bilo kojim od patentnih zahtjeva 1-6, koje je sposobno za specifično vezivanje SEQ ID NO: 15 koja predstavlja aminokiselinsku sekvencu A24T/Y28F/N30S/R32Q/E54K-cTREM-1-Cmyc2-His6.
8. Antitijelo u skladu sa bilo kojim od patentnih zahtjeva 1-7, teški lanac koji sadrži CDRH1 sekvencu koja odgovara aminokiselinskim ostacima 31 do 35 predstavljene pomoću aminokiselina TYAMH sa SEQ ID NO: 4, gdje jedan od ovih aminokiselinskih ostataka može biti zamijenjen sa drugačijim aminokiselinskim ostatkom; i/ili CDRH2 sekvencu koja odgovara aminokiselinama 50 do 68 koje su predstavljene pomoću aminokiselina RIRTKSSNYATYYAASVKG sa SEQ ID NO: 4, gdje jedna, dvije ili tri od spomenutih aminokiselina mogu biti zamijenjene sa drugačijim aminokiselinskim ostatkom; i/ili CDRH3 sekvencu koja odgovara aminokiselinskim ostacima 101 do 110 predstavljenih pomoću aminokiselina DMGIRRQFAY sa SEQ ID NO: 4, gdje jedan, dva ili tri od spomenutih aminokiselinskih ostataka mogu biti zamijenjeni sa drugačijom aminokiselinom; i laki lanac koji sadrži CDRL1 sekvencu koja odgovara aminokiselinskim ostacima 24 do 38 predstavljene pomoću aminokiselina RASESVDTFDYSFLH sa SEQ ID NO: 5, gdje jedan, dva ili tri od ovih aminokiselinskih ostataka mogu biti zamijenjeni sa drugačijom aminokiselinom; i/ili CDRL2 sekvencu koja odgovara aminokiselinskim ostacima 54 do 60 predstavljenih pomoću aminokiselina RASNLES sa SEQ ID NO: 5, gdje jedan ili dva od ovih aminokiselinskih ostataka mogu biti zamijenjeni sa drugačijom aminokiselinom; i/ili CDRL3 sekvencu koja odgovara aminokiselinskim ostacima 93 do 101 predstavljenih pomoću aminokiselina QQSNEDPYT sa SEQ ID NO: 5, gdje jedan ili dva od ovih aminokiselinskih ostataka mogu biti zamijenjeni sa drugačijom aminokiselinom.
9. Antitijelo u skladu sa patentnim zahtjevom 8, teški lanac koji sadrži CDRH1 sekvencu koja odgovara aminokiselinskim ostacima 31 do 35 predstavljenih pomoću aminokiselina TYAMH sa SEQ ID NO: 4; i/ili CDRH2 sekvencu koja odgovara aminokiselinama 50 do 68 predstavljenih pomoću aminokiselina RIRTKSSNYATYYAASVKG sa SEQ ID NO: 4; i/ili CDRH3 sekvencu koja odgovara aminokiselinskim ostacima 101 do 110 predstavljenih pomoću aminokiselina DMGIRRQFAY sa SEQ ID NO: 4; i laki lanac koji sadrži CDRL1 sekvencu koja odgovara aminokiselinskim ostacima 24 do 38 predstavljenih pomoću aminokiselina RASESVDTFDYSFLH sa SEQ ID NO: 5; i/ili CDRL2 sekvencu koja odgovara aminokiselinskim ostacima 54 do 60 predstavljenih pomoću aminokiselina RASNLES sa SEQ ID NO: 5; i/ili CDRL3 sekvencu koja odgovara aminokiselinskim ostacima 93 do 101 predstavljenih pomoću aminokiselina QQSNEDPYT sa SEQ ID NO: 5.
10. Antitijelo ili njegov fragment u skladu sa bilo kojim od patentnih zahtjeva 1-9 za primjenu kao medikament
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261598968P | 2012-02-15 | 2012-02-15 | |
| EP12155641 | 2012-02-15 | ||
| US201261599447P | 2012-02-16 | 2012-02-16 | |
| EP12158974 | 2012-03-12 | ||
| US201261672799P | 2012-07-18 | 2012-07-18 | |
| EP12176892 | 2012-07-18 | ||
| US201261674434P | 2012-07-23 | 2012-07-23 | |
| PCT/EP2012/074092 WO2013120553A1 (en) | 2012-02-15 | 2012-11-30 | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
| EP12794962.6A EP2814844B1 (en) | 2012-02-15 | 2012-11-30 | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171585T1 true HRP20171585T1 (hr) | 2017-12-01 |
Family
ID=48946140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171585TT HRP20171585T1 (hr) | 2012-02-15 | 2017-10-18 | Antitijela koja vezuju i blokiraju aktivirajući receptor eksprimiran na mijeloičnim stanicama 1 (trem-1) |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9000127B2 (hr) |
| EP (3) | EP3196214B1 (hr) |
| JP (2) | JP6411218B2 (hr) |
| CN (2) | CN104220456B (hr) |
| CY (1) | CY1120068T1 (hr) |
| DK (1) | DK2814844T3 (hr) |
| ES (1) | ES2640268T3 (hr) |
| HR (1) | HRP20171585T1 (hr) |
| HU (1) | HUE036955T2 (hr) |
| LT (1) | LT2814844T (hr) |
| NO (1) | NO2814844T3 (hr) |
| PL (1) | PL2814844T3 (hr) |
| PT (1) | PT2814844T (hr) |
| RS (1) | RS56593B1 (hr) |
| SI (1) | SI2814844T1 (hr) |
| TW (1) | TWI605061B (hr) |
| WO (1) | WO2013120553A1 (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2750209T3 (es) * | 2012-02-15 | 2020-03-25 | Novo Nordisk As | Anticuerpos que se unen a y bloquean al receptor desencadenante expresado en células mieloides-1 (TREM-1) |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| EP3196214B1 (en) * | 2012-02-15 | 2019-07-31 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
| EP2835641A1 (en) | 2013-08-09 | 2015-02-11 | Inotrem | Methods and kits for predicting the risk of having a cardiovascular disease or event |
| EP2975056A1 (en) | 2014-07-17 | 2016-01-20 | Novo Nordisk A/S | Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity |
| EP3026061A1 (en) | 2014-11-26 | 2016-06-01 | Novo Nordisk A/S | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity. |
| JP6738316B2 (ja) * | 2014-07-17 | 2020-08-12 | ノヴォ ノルディスク アクティーゼルスカブ | 粘度を低下させるためのｔｒｅｍ−１抗体の部位特異的変異誘発 |
| US10259882B2 (en) | 2015-05-07 | 2019-04-16 | Agenus Inc. | Anti-OX40 antibodies |
| US11213598B2 (en) * | 2015-11-12 | 2022-01-04 | The Board Of Trustees Of The Leland Stanford Junior University | Labeled probe and methods of use |
| US11447557B2 (en) | 2015-12-02 | 2022-09-20 | Agenus Inc. | Antibodies and methods of use thereof |
| JP7023853B2 (ja) * | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | 抗ｔｒｅｍ１抗体及びその使用方法 |
| CN106053831A (zh) * | 2016-06-05 | 2016-10-26 | 潘时辉 | 一种用于自身免疫病检测的试剂盒 |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| CN108276488B (zh) * | 2018-01-26 | 2020-06-19 | 四川农业大学 | 一种鸡髓样细胞触发受体b2多克隆抗体及其制备方法和应用 |
| US11155618B2 (en) | 2018-04-02 | 2021-10-26 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
| EP3836951A1 (en) | 2018-08-13 | 2021-06-23 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
| BR112021005808A2 (pt) | 2018-09-28 | 2021-07-27 | Inotrem | uso de níveis de trem-1 solúveis para identificar indivíduos suscetíveis a responder a uma terapia anti-inflamatória |
| US10836828B2 (en) | 2019-02-06 | 2020-11-17 | Pionyr Immunotherapeutics, Inc. | Anti-TREM1 antibodies and related methods |
| WO2021011678A1 (en) * | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| EP3999541A1 (en) | 2019-07-15 | 2022-05-25 | Bristol-Myers Squibb Company | Antibodies against human trem-1 and uses thereof |
| EP4065152A1 (en) | 2019-11-25 | 2022-10-05 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Trem-1 inhibitors for the treatment of vaso-occlusions and tissue injuries in patients suffering from sickle cell disease |
| CN111157741B (zh) * | 2019-12-30 | 2022-08-16 | 广州市妇女儿童医疗中心 | 髓系细胞触发受体1在制备胃炎诊断或治疗试剂中的应用及试剂盒 |
| EP4162275A1 (en) | 2020-06-05 | 2023-04-12 | Inotrem | Soluble trem-1 as a marker of severity or complications for a subject suffering from a coronavirus infection |
| WO2021245291A1 (en) | 2020-06-05 | 2021-12-09 | Inotrem | Trem-1 inhibitor for use in the treatment of a subject suffering from a coronavirus infection |
| CA3197465A1 (en) | 2020-11-02 | 2022-05-05 | UCB Biopharma SRL | Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders |
| EP4304626A1 (en) | 2021-03-12 | 2024-01-17 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Trem-1 inhibitors for the treatment of marfan syndrome |
| CA3218933A1 (en) * | 2021-05-03 | 2022-11-10 | UCB Biopharma SRL | Antibodies |
| CA3220167A1 (en) * | 2021-06-02 | 2022-12-08 | Marc Derive | Anti-trem-1 antibodies |
| WO2023061946A1 (en) | 2021-10-11 | 2023-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of trem-1 for predicting and preventing postoperative complications after cardiac surgery with cardiopulmonary by-pass |
| CN114948849A (zh) * | 2022-05-13 | 2022-08-30 | 苏州大学附属第一医院 | 一种含trem1抑制剂的微针、微针系统及其制备方法 |
Family Cites Families (171)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| ATE141646T1 (de) | 1986-04-09 | 1996-09-15 | Genzyme Corp | Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP2972257B2 (ja) | 1990-01-24 | 1999-11-08 | 株式会社日立製作所 | パケット交換機 |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL91501A (en) | 1988-09-02 | 1998-03-10 | Dyax Corp | Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| JPH04501510A (ja) | 1989-07-25 | 1992-03-19 | セル ジェネシス，インコーポレイティド | 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同性組換え |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| SG122763A1 (en) | 1989-11-06 | 2006-06-29 | Cell Genesys Inc | Production of proteins using homologous recombination |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ZW9091A1 (en) | 1990-07-10 | 1992-04-29 | Smithkline Beecham Corp | Oxamides |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| AU660629B2 (en) | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
| ATE199647T1 (de) | 1991-05-14 | 2001-03-15 | Univ Connecticut | Gerichtete abgabe von genen, die immunogene proteine kodieren |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1992022635A1 (en) | 1991-06-05 | 1992-12-23 | University Of Connecticut | Targeted delivery of genes encoding secretory proteins |
| JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
| AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| AU3940293A (en) | 1992-04-03 | 1993-11-08 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| FR2694851B1 (fr) | 1992-08-12 | 1994-12-23 | Sgs Thomson Microelectronics | Circuit de tirage vers un état déterminé d'une entrée de circuit intégré. |
| EP0749475A4 (en) | 1992-08-26 | 1997-05-07 | Harvard College | USE OF THE CYTOKIN IP-10 AS AN ANTI-TUMOR AGENCY |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| KR950703640A (ko) | 1992-10-09 | 1995-09-20 | 가일 케이,나우톤. | 간 보존 세포(liver reserve cells) |
| EP0672131B1 (en) | 1992-10-30 | 2003-12-17 | The General Hospital Corporation | A novel cell cycle control protein |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| WO1994016101A2 (en) | 1993-01-07 | 1994-07-21 | Koester Hubert | Dna sequencing by mass spectrometry |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| ATE300610T1 (de) | 1994-01-31 | 2005-08-15 | Univ Boston | Bibliotheken aus polyklonalen antikörpern |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| DE69737479T4 (de) | 1996-08-30 | 2010-05-06 | Novo Nordisk A/S | Glp-1 derivate |
| US6034217A (en) | 1996-09-17 | 2000-03-07 | Wako Pure Chemical Industries, Ltd. | Peptidoglycan recognition proteins and their production |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| WO1998039446A2 (en) | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 70 human secreted proteins |
| US20030049618A1 (en) | 1997-03-07 | 2003-03-13 | Ruben Steven M. | 186 human secreted proteins |
| US20030175858A1 (en) | 1997-03-07 | 2003-09-18 | Ruben Steven M. | 186 human secreted proteins |
| US6420526B1 (en) | 1997-03-07 | 2002-07-16 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| US6878687B1 (en) | 1997-03-07 | 2005-04-12 | Human Genome Sciences, Inc. | Protein HMAAD57 |
| CA2283299A1 (en) | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| WO1998049198A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6172211B1 (en) | 1997-07-11 | 2001-01-09 | Boehringer Ingelheim International Gmbh | Nucleic acid encoding tag7 polypeptide |
| US20020102542A1 (en) | 1997-10-07 | 2002-08-01 | Daikichi Fukushima | Polypeptide, cdna encoding the polypeptide, and use of the both |
| AU4834999A (en) | 1998-06-26 | 2000-01-17 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
| US20020197669A1 (en) | 2000-12-13 | 2002-12-26 | Bangur Chaitanya S. | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030170255A1 (en) | 1999-06-30 | 2003-09-11 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6858204B2 (en) | 1999-06-30 | 2005-02-22 | Corxia Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20020172952A1 (en) | 1999-06-30 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6504010B1 (en) | 1999-06-30 | 2003-01-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6509448B2 (en) | 1999-06-30 | 2003-01-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030211510A1 (en) | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| EP1242443A4 (en) | 1999-12-23 | 2005-06-22 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
| AU2001274888A1 (en) | 2000-05-19 | 2001-12-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20030134283A1 (en) | 2000-10-03 | 2003-07-17 | Peterson David P. | Genes regulated in dendritic cell differentiation |
| JP2004522742A (ja) | 2000-12-08 | 2004-07-29 | ベイラー カレッジ オブ メディシン | 免疫応答の改変において使用するためのｔｒｅｍ−１スプライス改変体 |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2342376C (en) * | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| WO2003029401A2 (en) | 2001-07-13 | 2003-04-10 | Advanced Research And Technology Institute | Peptidoglycan recognition protein encoding nucleic acids and methods of use thereof |
| WO2003011213A2 (en) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
| AU2002330039A1 (en) | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
| WO2003030835A2 (en) | 2001-10-12 | 2003-04-17 | Schering Corporation | Use of bispecific antibodies to regulate immune responses |
| ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
| EP1329227A1 (en) | 2002-01-22 | 2003-07-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells |
| EP1530590A2 (en) | 2002-03-22 | 2005-05-18 | Bioxell S.p.a. | Triggering receptors expressed on myeloid cells (trem)-4 and -5 and uses thereof |
| WO2004020591A2 (en) | 2002-08-29 | 2004-03-11 | Five Prime Therapeutics, Inc. | Methods of use for novel human polypeptides encoded by polynucleotides |
| GB0305478D0 (en) | 2003-03-10 | 2003-04-16 | Bioxell Spa | Diagnostic and prognostic compounds and method |
| US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
| DE10316701A1 (de) | 2003-04-09 | 2004-11-04 | Hinzmann, Bernd, Dr. | Humane Nukleinsäuresequenzen aus Bronchialkarzinomen |
| US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| EP1692506A4 (en) | 2003-11-17 | 2008-01-09 | Janssen Pharmaceutica Nv | MODELING A SYSTEMIC INFLAMMATORY RESPONSE TO INFECTION |
| GB0401730D0 (en) | 2004-01-27 | 2004-03-03 | Bioxell Spa | Diagnosis method |
| EP1735340A2 (en) | 2004-03-17 | 2006-12-27 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
| WO2005113606A2 (en) | 2004-05-13 | 2005-12-01 | Eli Lilly And Company | Fgf-21 fusion proteins |
| WO2006028595A2 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| WO2006028714A1 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| JP2008522617A (ja) | 2004-12-14 | 2008-07-03 | イーライ リリー アンド カンパニー | 線維芽細胞成長因子２１の突然変異タンパク質 |
| JP2008528487A (ja) | 2005-01-21 | 2008-07-31 | イーライ リリー アンド カンパニー | 心臓血管疾患を治療する方法 |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| AU2006259583A1 (en) | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| EP2076272B1 (en) | 2006-10-19 | 2015-07-29 | Baylor College Of Medicine | Generating an immune response by inducing cd40 and pattern recognition receptors |
| JP2010516678A (ja) * | 2007-01-16 | 2010-05-20 | ワイス エルエルシー | Ｔｒｅｍ−１による炎症治療、検出およびモニタリング |
| KR101476472B1 (ko) | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| EP2069401A4 (en) | 2007-07-31 | 2011-02-23 | Medimmune Llc | MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE |
| EP3260129A1 (en) | 2007-08-03 | 2017-12-27 | Eli Lilly and Company | An fgf-21 compound and a glp-1 compound for use in the treatment of obesity |
| EP2185701A4 (en) | 2007-08-15 | 2011-03-02 | Amunix Operating Inc | COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES |
| EP2190460B1 (en) | 2007-09-05 | 2014-12-17 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| CA2709217C (en) | 2007-12-19 | 2021-01-05 | Singulex, Inc. | Scanning analyzer for single molecule detection and methods of use |
| CN102016552A (zh) | 2008-03-05 | 2011-04-13 | 神谷来克斯公司 | 用于分子的高灵敏性检测的方法和组合物 |
| WO2009141359A1 (en) | 2008-05-23 | 2009-11-26 | Pronota N.V. | New biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof |
| SG192489A1 (en) | 2008-07-08 | 2013-08-30 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| US20110160085A1 (en) | 2008-08-25 | 2011-06-30 | Katherine Li | Biomarkers for anti-tnf treatment in ulcreative colitis and related disorders |
| MX341149B (es) | 2008-10-10 | 2016-08-09 | Amgen Inc | Mutantes fgf21 y uso de los mismos. |
| WO2010065439A1 (en) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| US9480753B2 (en) | 2009-01-23 | 2016-11-01 | Novo Nordisk A/S | FGF21 derivatives with albumin binder A-B-C-D-E- and their use |
| WO2010132370A2 (en) | 2009-05-11 | 2010-11-18 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Soluble tlt-1 for the treatment and diagnosis of sepsis |
| WO2010141469A2 (en) | 2009-06-01 | 2010-12-09 | Case Western Reserve University | Protein biomarkers and therapeutic targets for autoimmune and alloimmune diseases |
| US20120172298A1 (en) | 2009-06-11 | 2012-07-05 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
| US20120213705A1 (en) | 2009-06-22 | 2012-08-23 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| WO2011047097A2 (en) | 2009-10-13 | 2011-04-21 | Sigalov Alexander B | Inhibition of trem receptor signaling with peptide variants |
| KR101251023B1 (ko) | 2009-11-05 | 2013-04-03 | 주식회사유한양행 | 신규한 단일클론항체를 포함하는 박테리아 감염 검출용 키트 |
| KR20120123299A (ko) | 2009-12-04 | 2012-11-08 | 제넨테크, 인크. | 다중특이적 항체, 항체 유사체, 조성물 및 방법 |
| US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
| SG185107A1 (en) | 2010-04-30 | 2012-12-28 | Alexion Pharma Inc | Antibodies having reduced immunogenicity in a human |
| US20130330350A1 (en) | 2010-11-09 | 2013-12-12 | Medimmune, Llc | Antibody Scaffold For Homogenous Conjugation |
| UY33826A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión con dominios trivariables y sus usos |
| UY33827A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión a media-inmunoglobulina y sus usos |
| WO2012109624A2 (en) | 2011-02-11 | 2012-08-16 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| CN103890097B (zh) * | 2011-08-31 | 2017-06-09 | 英威达技术有限公司 | 多元醇和聚酰胺的组合物 |
| EP3196214B1 (en) * | 2012-02-15 | 2019-07-31 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
-
2012
- 2012-11-30 EP EP17156557.5A patent/EP3196214B1/en active Active
- 2012-11-30 PT PT127949626T patent/PT2814844T/pt unknown
- 2012-11-30 US US13/690,748 patent/US9000127B2/en active Active
- 2012-11-30 CN CN201280072409.3A patent/CN104220456B/zh active Active
- 2012-11-30 TW TW101145217A patent/TWI605061B/zh active
- 2012-11-30 CN CN201810059151.2A patent/CN108103069B/zh active Active
- 2012-11-30 DK DK12794962.6T patent/DK2814844T3/da active
- 2012-11-30 LT LTEP12794962.6T patent/LT2814844T/lt unknown
- 2012-11-30 EP EP19182096.8A patent/EP3611190A1/en active Pending
- 2012-11-30 EP EP12794962.6A patent/EP2814844B1/en active Active
- 2012-11-30 HU HUE12794962A patent/HUE036955T2/hu unknown
- 2012-11-30 NO NO12794962A patent/NO2814844T3/no unknown
- 2012-11-30 PL PL12794962T patent/PL2814844T3/pl unknown
- 2012-11-30 RS RS20171103A patent/RS56593B1/sr unknown
- 2012-11-30 ES ES12794962.6T patent/ES2640268T3/es active Active
- 2012-11-30 SI SI201231042T patent/SI2814844T1/sl unknown
- 2012-11-30 WO PCT/EP2012/074092 patent/WO2013120553A1/en active Application Filing
- 2012-11-30 JP JP2014556934A patent/JP6411218B2/ja active Active
-
2015
- 2015-02-26 US US14/632,079 patent/US20150274825A1/en not_active Abandoned
-
2017
- 2017-10-17 CY CY20171101082T patent/CY1120068T1/el unknown
- 2017-10-18 HR HRP20171585TT patent/HRP20171585T1/hr unknown
-
2018
- 2018-09-26 JP JP2018180187A patent/JP6740308B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RS56593B1 (sr) | 2018-02-28 |
| HUE036955T2 (hu) | 2018-08-28 |
| JP2015508762A (ja) | 2015-03-23 |
| US9000127B2 (en) | 2015-04-07 |
| EP2814844B1 (en) | 2017-08-02 |
| EP3196214A1 (en) | 2017-07-26 |
| CN108103069A (zh) | 2018-06-01 |
| TW201335186A (zh) | 2013-09-01 |
| JP6411218B2 (ja) | 2018-10-24 |
| US20130211050A1 (en) | 2013-08-15 |
| EP3611190A1 (en) | 2020-02-19 |
| PT2814844T (pt) | 2017-09-18 |
| EP2814844A1 (en) | 2014-12-24 |
| NO2814844T3 (hr) | 2017-12-30 |
| JP2018203777A (ja) | 2018-12-27 |
| JP6740308B2 (ja) | 2020-08-12 |
| CN104220456A (zh) | 2014-12-17 |
| ES2640268T3 (es) | 2017-11-02 |
| PL2814844T3 (pl) | 2017-12-29 |
| LT2814844T (lt) | 2017-10-25 |
| SI2814844T1 (sl) | 2017-10-30 |
| EP3196214B1 (en) | 2019-07-31 |
| WO2013120553A1 (en) | 2013-08-22 |
| US20150274825A1 (en) | 2015-10-01 |
| CN104220456B (zh) | 2018-02-23 |
| DK2814844T3 (da) | 2017-11-13 |
| TWI605061B (zh) | 2017-11-11 |
| CY1120068T1 (el) | 2018-12-12 |
| CN108103069B (zh) | 2021-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171585T1 (hr) | Antitijela koja vezuju i blokiraju aktivirajući receptor eksprimiran na mijeloičnim stanicama 1 (trem-1) | |
| JP2015508762A5 (hr) | ||
| HRP20170882T1 (hr) | Humani antigen-vezujući proteini koji se vežu za beta-klotho, fgf receptore i njihove komplekse | |
| RU2016119152A (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| HRP20201503T1 (hr) | MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79 | |
| HRP20200464T1 (hr) | Metoda modifikacije polipeptida za pročišćavanje polipeptidnih multimera | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| HRP20210389T1 (hr) | Višespecifične konstrukcije antitijela | |
| HRP20190714T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| IL257281A (en) | Anti-pd-1 antibodies and methods of using them | |
| JP2020500538A5 (hr) | ||
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| RU2020129387A (ru) | Антитела к pd-1 собак | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| JP2018536393A5 (hr) | ||
| PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
| RU2017104815A (ru) | Молекулы со специфичностью в отношении cd79 и cd22 | |
| JP2012116856A5 (hr) | ||
| JP2015508763A5 (hr) | ||
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| RS54846B1 (sr) | Novo anti-dr5 antitelo | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| PE20161439A1 (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos | |
| JP2014519522A5 (hr) |